implantation, with PaO2/FIo2 ratio increasing from 79±20 to 112±47 and PaCO2-VE product decreasing from 7.6±4.2 to 4.9±2.5 within 4 h. A significant reduction in peak inspiratory pressure was achieved (45 ± 10 to 38 ± 9 cm 1120). Major complications were blood loss during implantation requiring transfusion in 11 patients, a retroperitoneal bleed in 1 as the 1975 NIH trial was reported by Morris et a18 in 1994. The control group in this study comparing pressure-controlled inverse ratio ventilation (PC-IRV) with PC-IRV and extracorporeal carbon dioxide removal, according to a rigidly controlled protocol, had a mortality of 58%, suggesting that carefully applied ventilator and patient management may reduce mortality. Nevertheless, mortality in patients with severe ARDS remains high, and efforts to further reduce it remain the subject of both laboratory and clinical research. Basic pathophysiologic changes in ARDS include intrapulmonary shunting and elevated dead-space resulting in impaired exchange of oxygen and carbon dioxide. Hypoxemia and hypercarbia can become pronounced, and are treated with mechanical ventilation and positive airway pressure with increased inspired oxygen fraction (FIo2), minute ventilation (VE), and positive end-expiratory pressure (PEEP). Excessive pressures can develop in the distal airways and alveoli. Since there is marked inhomogeneity in ventilation, more compliant areas of the lung undergo overdistention and increase the risk of injury. Attempts to deliver tidal volumes necessary for CO2 removal in this setting can worsen the injury. Evidence has been accumulating for 30 years that the intensity of mechanical ventilatory support, in particular the levels of airway pressure and lung volume, required in ARDS to maintain adequate blood gas tensions can create and potentiate injury to the parenchyma through this overdistention of distal airways and alveoli. [9] [10] [11] [12] [13] [14] Volume-induced pulmonary trauma is difficult to identify and assess, since in its early stages, the clinical, radiographic, and histologic picture is usually similar to the underlying disease process of ARDS. into position in the venae cavae. Once in place, the gas exchange bundle extends from the inferior vena cava to the superior vena cava, traversing the right atrium. The support catheter contains gas supply and exhaust conduits. A gas controller supplies oxygen via negative pressure on the exhaust line, to maintain a negative intraluminal gas pressure. Gas exchange takes place between the intraluminal gas phase and the extraluminal blood phase by diffusion across the siloxane membrane. Table 3 .
Effects on Mechanical Ventilatory Support
The FIo2 was significantly reduced from a baseline of 0.78 ± 16 to 0.63 ± 21 by 4 h postimplantation and to 0.57 ± 18 by 12 h postimplantation (Fig 1, top [A] ). The FIo2 remained significantly lower for the remainder of the 48-h study period. This reduction was achieved despite a rise in PaO2, although this Time After Implantation (hrs) 40 not reach significance since our goal was to maintain a stable SaO2 of 90 to 92%. Minute ventilation was reduced significantly by 4 h postimplantation from 177 ± 94 to 127±58 mL * kg * min-, and remained low for the 48-h study period (Fig 1, center [B] ). This reduction in VE was a result of decreases in tidal volume and respiratory rate. The Pco2 remained relatively constant despite the reduction in VE over the evaluation period. The device permitted a reduction in peak inspiratory pressure from 46 cm H20 to 42 and 38 cm H20 by 4 and 12 h postimplantation, respectively (Fig 1,  bottom [C] ). (Fig 2, bottom [ (Fig 3) . There was no significant change in mean systemic arterial pressure, heart rate, pulmonary artery pressure, or RAP.
All hemodynamic indices remained stable from 4 h postimplantation through the remainder of the 48-h observation period. 
Hematologic Effects
A reduction in platelet count was encountered during the study (Fig 4, top [A] ). Levels patients; this was confirmed by repeated ultrasound examination. None of the four patients had clinical evidence of pulmonary embolism. The one patient receiving streptokinase had a negative pulmonary ventilation-perfusion radionuclide scan, and the remaining patients were not studied. There were no instances of wound, device, or blood-borne infection in any patient. Four patients had sepsis prior to device implantation, of whom two had bacteremia treated with antibiotics prior to implantation, with negative blood cultures by the time the device was implanted.
Examination of the device following explantation in survivors and nonsurvivors revealed slight agglutination of some of the fibers due to platelet-fibrin deposition, but was limited to less than 5% of the gas exchange surface. Small thrombi were identified within the interior of the fiber bundle at the junction of the proximal and distal manifolds in all devices, but were tightly adherent and not considered significant. No thrombus formation was found on the gas exchange surface of any of the devices.
Necropsy Findings
Necropsy was performed on eight patients. The causes of death included peritonitis and diffuse alveolar damage in one patient, severe pneumonia with diffuse alveolar damage in two patients, near drowning with ARDS in one patient, and diffuse alveolar damage (ARDS) in the remaining four patients. The causes of death indicated by necropsy were consistent with the clinically indicated causes of death in all cases. There were no findings to suggest IVOX contributed to death in any patient. The only unexpected finding was a pelvic retroperitoneal hematoma (in the patient requiring wound exploration) of approximately 150 mL in size. Survival
Ten patients survived the course of ARDS and were transferred from the ICU. Two of these patients died subsequent to ICU care, and eight were discharged from the hospital alive. This represents a short-term survival of 50% and discharge survival of 40% of patients who completed device implantation.
There was no statistical difference between survivors and nonsurvivors with respect to age, prior duration of respiratory failure, lung injury score, cardiac index, PaO2/FIo2, lung compliance, or intrapulmonary shunt (Table 4 ). There was a higher incidence of multiple organ dysfunction at study entry in nonsurvivors as compared with survivors (5/10 vs 1/10), but the difference did not reach statistical significance (p=0.14).
DISCUSSION
The application of airway pressure therapy is currently the accepted means to support impaired gas exchange in respiratory failure. Patients with severe respiratory failure who require elevated levels of inspired oxygen and minute ventilation continue to have a high mortality. Since airway pressure therapy does not reverse the underlying pathophysiologic condition, improved outcome must await more definitive therapy. There is ample evidence, however, that the application of excessive airway pressure not only can result in classic barotrauma syndromes (pneumomediastinum, pneumatoceles, pneumothorax), but may enhance or propagate the underlying parenchymal injury in respiratory failure.9'14,21 The hypothesis that reducing airway pressures in respiratory failure may lead to decreased pulmonary injury has led to the clinical application of techniques to limit alveolar overdistention. Hickling et al,22 in an uncontrolled trial, reported a lower mortality in patients with ARDS through the use of low-volume pressure-limited ventilation and permissive hypercapnia. Morris et a18 reported a 42% survival in a group of patients treated with pressure-controlled inverse ratio ventilation using a rigidly controlled management protocol in patients whose entry criteria have previously been associated with up to 90% mortality. Extracorporeal support of gas exchange, including extracorporeal CO2 removal and venovenous ECMO can permit substantial reductions in requirements for ventilatory support. By transferring gas exchange function to the extracorporeal circuit, more substantial reductions in ventilator support (lung rest) are possible. Recent series of venovenous extracorporeal and CO2 removal report survival rates of 50% and higher. [16] [17] [18] Extracorporeal techniques, however, are resource There were no episodes of septicemia associated with use of IVOX. The potential for microbiologic colonization would appear to be great based on the large surface area of the device (up to 0.52 M2). However, no patient developed bacteremia or fungemia, and all cultures of the devices following explantation were negative despite implantation periods of up to 20 days. The use of prophylactic antibiotics likely contributed to the lack of incidence of infection, but the safety of the device with regard to infectious complications appears quite good.
We encountered minimal morbidity and no mortality directly associated with application of IVOX. The principal morbidities encountered were blood loss at the time of implantation, bleeding complications of anticoagulation, and deep venous thrombosis. The only hematologic effect noted was a decrease in platelet count. It The contribution of gas exchange by IVOX to total patient requirements was restricted and represents the major limitation of the device in its present form. Despite this restriction, gas exchange levels are comparable to low-flow extracorporeal venovenous support. This preliminary and uncontrolled trial, although confirming the feasibility and relative safety of partial intracorporeal support of gas exchange, is subject to the limitations of a small, single-center trial and needs to be supported by larger, prospective comparative trials. Enhancements to the performance of the existing device could expand the role of intracorporeal support of severe respiratory failure.
